open access
Biopodobne leki biologiczne w reumatologii
open access
Abstract
Abstract
Keywords
leki biologiczne; leki biopodobne; leczenie chorób reumatycznych
Title
Biopodobne leki biologiczne w reumatologii
Journal
Issue
Article type
Review paper
Pages
191-204
Published online
2018-01-22
Page views
1309
Article views/downloads
4347
Bibliographic record
Forum Reumatol 2017;3(4):191-204.
Keywords
leki biologiczne
leki biopodobne
leczenie chorób reumatycznych
Authors
Eugeniusz Józef Kucharz
Marcin Stajszczyk
Bogdan Batko
Marek Brzosko
Sławomir Jeka
Anna Kotulska
Maria Majdan
Włodzimierz Samborski
Jerzy Świerkot
Piotr Wiland
Zbigniew Żuber
- Rasi G. Foreword. In: Rasi G. ed. Biosimilars in EU. Information guide for healthcare professionals. European Medicines Agency. European Commission. 2017: 2.
- Laraia L, Waldmann H. Natural product inspired compound collections: evolutionary principle, chemical synthesis, phenotypic screening, and target identification. Drug Discov Today Technol. 2017; 23: 75–82.
- Vezér B, Buzás Z, Sebeszta M, et al. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016; 32(5): 829–834.
- Feldman SR. Inflammatory diseases: Integrating biosimilars into clinical practice. Semin Arthritis Rheum. 2015; 44(6 Suppl): S16–S21.
- Blandizzi C, Meroni PL, Lapadula G. Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clin Ther. 2017; 39(5): 1026–1039.
- Jedrzejczak WW. Leki biopodobne w hematologii. Acta Haematol Pol. 2009; 40: 563–568.
- Nowicki M, Zimmer-Nowicka J. Biofarmaceutyki oryginalne i leki biopodobne – co należy wiedzieć, aby zapewnić bezpieczeństwo leczenia? Onkol Prakt Klin. 2007; 3: 120–127.
- Grieb P. Kompendium na temat leków biopodobnych. Forum Nefrol. 2011; 4: 193–197.
- Mehr SR, Zimmerman MP. Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today? Am Health Drug Benefits. 2016; 9(9): 515–518.
- Ghia C, Shah D, Rambhad G, et al. Biologics, biosimilars, intended copies and the era of competitive medicine. Apollo Medicine. 2015; 12(2): 103–111.
- Schellekens H, Lietzan E, Faccin F, et al. Biosimilar monoclonal antibodies: the scientific basis for extrapolation. Expert Opin Biol Ther. 2015; 15(11): 1633–1646.
- Lie G, Sciascia S, Cuadrado MJ. Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough? Int Immunopharmacol. 2015; 27(2): 220–223.
- Tesser JRp, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017; 11: 5–11.
- Tabernero J, Vyas M, Giuliani R, et al. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. ESMO Open. 2016; 1(6): e000142.
- Braun J, Kay J. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2017; 16(3): 289–302.
- Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016; 75(6): 974–982.
- Jørgensen KK, Olsen IC, Goll GL, et al. NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017; 389(10086): 2304–2316.
- Schmitz EMH, Benoy-De Keuster S, Meier AJL, et al. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol. 2017; 36(9): 2129–2134.
- Glintborg B, Sørensen IJ, Loft AG, et al. all departments of rheumatology in Denmark. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017; 76(8): 1426–1431.
- Inotai A, Prins CPJ, Csanádi M, et al. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther. 2017; 17(8): 915–926.
- Moots R, Azevedo V, Coindreau JL, et al. Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. Curr Rheumatol Rep. 2017; 19(6): 37.
- Kay J, Schoels MM, Dörner T, et al. Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2017 [Epub ahead of print].
- Kucharz EJ. Stanowisko Unii Europejskiej w sprawie leków biopodobnych. Reumatologia News. 2017; 2: 77–79.
- http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit (24.10.2017).
- Lee H, Chung H, Lee S, et al. LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects. BioDrugs. 2017 [Epub ahead of print].
- Azevedo V, Galli N, Kleinfelder A, et al. Etanercept biosimilars. Rheumatology International. 2014; 35(2): 197–209.
- https://google2.fda.gov/search?q=adalimumab&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=-archive%3AYes&output=xml_no_dtd&getfields=* (24.10.2017).
- Baji P, Péntek M, Szántó S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014; 15 Suppl 1: S45–S52.
- Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72(10): 1613–1620.
- Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016; 18: 25.
- Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017; 76(2): 346–354.
- Taylor P. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases. Expert Rev Clin Immunol. 2015; 11 Suppl 1: S1–S4.
- Yoo DH. CT-P13 in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2017; 13(7): 653–666.
- Jørgensen KK, Olsen IC, Goll GL, et al. NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017; 389(10086): 2304–2316.
- Chang S, Hanauer S. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2017; 15(1): 53–70.
- Griffiths CEM, Thaçi D, Gerdes S, et al. EGALITY study group. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017; 176(4): 928–938.
- Emery P, Vencovský J, Sylwestrzak A, et al. Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. Ann Rheum Dis. 2017 [Epub ahead of print].
- Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Arthritis Rheumatol. 2017 [Epub ahead of print].
- Park W, Suh CH, Shim SC, et al. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis. BioDrugs. 2017 [Epub ahead of print].
- Glintborg B, Sørensen IJ, Loft AG, et al. all departments of rheumatology in Denmark. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017; 76(8): 1426–1431.
- Glintborg B, Sørensen IJ, Loft AG. Clinical outcomes from a natiowide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow up. Results from the DANBIO registry. Ann Rheum Dis. 2017; 76: 553.
- Kanters TA, Stevanovic J, Huys I, et al. Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel. Front Pharmacol. 2017; 8: 322.
- Gulácsi L, Brodszky V, Baji P, et al. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Adv Ther. 2017; 34(5): 1128–1144.
- Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014; 15 Suppl 1: S65–S71.
- Gulácsi L, Brodszky V, Baji P, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol. 2015; 11 Suppl 1: S43–S52.
- Kucharz EJ. Reumatolog na rozdrożu, czyli o biologicznych lekach biopodobnych. Reumatologia. 2014; 52: 86–88.
- Hemmington A, Dalbeth N, Jarrett P, et al. Medical specialists' attitudes to prescribing biosimilars. Pharmacoepidemiol Drug Saf. 2017; 26(5): 570–577.
- Waller J, Sullivan E, Piercy J, et al. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany. Patient Prefer Adherence. 2017; 11: 519–530.